Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25344 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Enrico De Lorenzis und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Leeds, Leeds, United Kingdom, and Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Biomarkers, Chemokine CCL24, Severity of Illness Index. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leeds NIHR Biomedical Research Centre, ChemomAb Ltd.
Abstract (Originalsprache)
Background
Systemic sclerosis (SSc) is a heterogeneous disease, characterized by variable tissue and vascular fibrosis in the context of autoimmune activation. CCL24 (or Eotaxin2) has been shown to promote microangiopathic, proinflammatory, and profibrotic processes in preclinical models of SSc. Here, we study serum CCL24 levels in a real‐life cohort of patients with SSc, to determine its distribution across disease features and its value in predicting disease progression and related mortality.
Methods
Serum CCL24 was assessed in an observational cohort of consecutively enrolled patients with SSc. A high CCL24 cutoff was defined based on its distribution in a matched cohort of healthy controls. Disease progression and mortality were analyzed from the date of serum assessment.
Results
Two‐hundred thirteen consecutively enrolled patients with SSc were included in this analysis. Median disease duration was six years (interquartile range 3–14), 28.6% of patients presented with interstitial lung disease (ILD), 46.9% had digital ulcers, and 25.3% showed high CCL24 serum concentration. High‐CCL24 patients were more frequently male and positive for anti–scl‐70, with a diagnosis of ILD and synovitis ( P < 0.05 for all). Notably, high‐CCL24 patients had lower diffusion of carbon monoxide and higher prevalence of digital ulcers, telangiectasias, and calcinosis ( P < 0.05 for all). In a longitudinal setting, high CCL24 was associated with greater lung function decline and with higher disease‐related mortality.
Conclusion
Serum CCL24 is a biomarker of disease severity across fibrotic and vascular disease manifestations. These data support the development of therapies targeting CCL24 as a novel comprehensive therapeutic target in SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Leeds, Leeds, United Kingdom, and Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- ChemomAb Ltd, Tel Aviv, Israel.
- University of Leeds, Leeds, United Kingdom.
- University of Leeds and NIHR Leeds Biomedical Research Centre - Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
ORCID-Profile: Enrico De Lorenzis, Francesco Del Galdo
Förderung
- Leeds NIHR Biomedical Research Centre
- ChemomAb Ltd
Zitieren
APA
De Lorenzis, E., Mor, A., Ross, R. L., Di Donato, S., Aricha, R., Vaknin, I., & Del Galdo, F. (2024). Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis. Arthritis Care & Research. https://doi.org/10.1002/acr.25344
Vancouver
De Lorenzis E, Mor A, Ross RL, Di Donato S, Aricha R, Vaknin I, et al. Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis. Arthritis Care & Research. 2024. doi:10.1002/acr.25344
BibTeX
@article{DeLorenzis2024,
author = {De Lorenzis, Enrico and Mor, Adi and Ross, Rebecca L and Di Donato, Stefano and Aricha, Revital and Vaknin, Ilan and Del Galdo, Francesco},
title = {Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25344}
}
EUVIMED